We investigated if BLM deficiency would affect sensitivity of human glioma cells to chemotherapeutics, thus we treated LN18 and LN229 BLM WT and KO cells with TMZ (Fig. 3A), OLA (Fig. 3B) or with TMZ and OLA combination (Fig. 3C). Here, BLM is linked to central nervous system cancer.